Abbott Laboratories (ABT)
Health Care12 articles
Price chart
Why is ABT moving today?
+0.2%ABT is +0.2% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 7 hours ago
Abbott Laboratories (ABT) overview
Abbott Laboratories is a diversified healthcare company spanning diagnostics, medical devices, and nutrition.
ABT is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Abbott Laboratories trades on the NYSE under the ticker symbol ABT. The most recent market data puts the share price at about $104.89. That is up 0.20% on the session. At that price the company is worth roughly $181.50B.
Over the past 52 weeks, ABT has traded between $81.97 and $132.03. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 33.8. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. ABT also pays a dividend. It yields around 2.41% at the current price.
Key statistics
Source: Yahoo Finance - quote as of 7 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch ABT
ABT is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each ABT story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. ABT is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves ABT
- Earnings. ABT reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from ABT.
- Sector news. Health Care stocks often move together, so a rival's news can move ABT too.
- Index weight. ABT is big enough to move the S&P 500 on its own.
Market Mood
Latest ABT news
Abbott Labs Upgraded by Rothschild Redburn for Device Strength
Rothschild Redburn has upgraded Abbott Laboratories' (ABT) stock rating, citing strong performance in its medical device segment. This upgrade reflects confidence in the company's growth potential amid a competitive landscape. The specific rating levels and projections were not disclosed in the article. Such upgrades can positively influence investor sentiment and stock price movement for Abbott Labs, positioning it favorably in a challenging market.
Read More: Abbott Labs Upgraded by Rothschild Redburn for Device Strength
AirBaltic (ABT) Files for Chapter 11 Bankruptcy in New York
AirBaltic has filed for Chapter 11 bankruptcy protection in New York. This filing indicates significant financial distress for the airline, which may affect its operations moving forward. The impact of this bankruptcy process will be closely monitored by investors and stakeholders in the airline industry. Such a filing often leads to restructuring efforts and potential asset sales, which could further influence market perceptions and valuations in the sector. This matters as it could impact not only AirBaltic but also investor sentiment towards similar stocks.
Read More: AirBaltic (ABT) Files for Chapter 11 Bankruptcy in New York
Abbott Laboratories (ABT) Target Raised to $143 with 35% Upside
Abbott Laboratories (ABT) trades at $105.70 with a P/E ratio of 19x forward earnings. Barclays analyst Matt Miksic has set a target price of $143, indicating a potential upside of 35%. Following the acquisition of Exact Sciences for $21 billion, Abbott raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60. Despite year-to-date declines of 16% and a revenue of $12.59 billion, analysts expect accelerating sales and earnings growth in H2 2026, positioning the company as a potential recovery play for investors.
Read More: Abbott Laboratories (ABT) Target Raised to $143 with 35% Upside
Abbott Laboratories (ABT) Faces Class-Action Lawsuit Over PediaSure
A federal judge ruled that Abbott Laboratories (ABT) must face a class-action lawsuit regarding allegations it misled consumers about PediaSure Grow & Gain drinks being 'clinically proven' for children's growth. The lawsuit claims the marketing could mislead consumers into interpreting growth as height gain, while using labels suggesting weight gain. Plaintiff Joanne Noriega alleges her grandson remained short after a year of daily use. Abbott maintains its labeling is appropriate and evidence-based, stating PediaSure supports children's growth and development.
Read More: Abbott Laboratories (ABT) Faces Class-Action Lawsuit Over PediaSure
Abbott Labs (ABT) to Report Q2 Earnings on July 16, Growth Insights
Abbott Laboratories (ABT) is set to report its second-quarter earnings on July 16. In Q1, the company's medical device revenue reached approximately $5.5 billion, contributing about 50% of total sales. The FreeStyle Libre platform alone generated roughly $2 billion in sales, with over 7 million users globally. The cardiovascular segment also showed growth, with $578 million in revenue. These figures highlight Abbott's diverse business structure and position in the medical device market, which could impact investor decisions leading up to the earnings announcement.
Read More: Abbott Labs (ABT) to Report Q2 Earnings on July 16, Growth Insights
Adeptus Biotechnologies Stock Rating Maintained by BTIG
BTIG has reiterated its stock rating on Adeptus Biotechnologies, following the company's strategic decision to split its business. This move is intended to focus on core areas and potentially unlock shareholder value. No specific numbers related to financial metrics or projected impacts are available in the report. The decision is positioned to strengthen Adeptus's market presence and operational efficiency, impacting investor sentiment positively.
Read More: Adeptus Biotechnologies Stock Rating Maintained by BTIG
Abbott Laboratories (ABT) Director Daniel Starks Buys $926,537 in Shares
Daniel Starks, a director at Abbott Laboratories (ABT), purchased $926,537 worth of shares. This transaction signifies his confidence in the company's future performance. The noteworthy investment could influence investor perception and potentially affect share prices. Transactions of this scale often draw attention, as they may indicate insider optimism about the company's current and upcoming market conditions.
Read More: Abbott Laboratories (ABT) Director Daniel Starks Buys $926,537 in Shares
Abbott Labs (ABT) stock price target cut to $120 by Benchmark
Benchmark has reduced its price target for Abbott Labs (ABT) stock to $120. This change reflects a re-evaluation of the company's valuation metrics. Such a downgrade can influence market perceptions and potentially impact stock performance. It is essential to monitor how this adjustment affects trading volume and investor sentiment moving forward.
Read More: Abbott Labs (ABT) stock price target cut to $120 by Benchmark
Abbott (ABT) Faces 20% Drop Amid Earnings Concerns and Lawsuit
Abbott Laboratories (ABT) has seen its stock decline 20% this year, influenced by a recent earnings report and ongoing legal issues concerning its special baby formula. Jim Cramer highlighted that Abbott recently acquired Exact Sciences for approximately $21 billion, a deal representing a 51% premium over its prior trading price, marking the largest healthcare merger in two years. Despite this acquisition, Abbott's stock has fallen more than $6 in two days following the announcement. Investors are cautious and awaiting additional insights during the upcoming earnings call to assess future growth potential.
Read More: Abbott (ABT) Faces 20% Drop Amid Earnings Concerns and Lawsuit
Abbott (ABT) Jury Orders $53 Million Payment in Formula Case
A jury has ordered Abbott (ABT) to pay $53 million following a trial related to preterm infant formula. This ruling could have significant implications for Abbott's financial position and market perception, especially in terms of product liability risks. The outcome of the trial may influence future litigation and customer trust in the company's products. Market analysts may watch for potential impacts on Abbott's stock price and overall valuation as a result.
Read More: Abbott (ABT) Jury Orders $53 Million Payment in Formula Case
Abbott Laboratories Completes Acquisition of Exact Sciences, Strengthens Market Position
On March 23, 2026, Abbott Laboratories (NYSE: ABT) completed the acquisition of Exact Sciences, positioning itself as a leader in the cancer screening and diagnostics market. This acquisition adds a significant growth vertical to Abbott's high-single-digit growth outlook and aims to address a $60 billion U.S. market focused on cancer screening and precision oncology diagnostics. Following the acquisition, Exact Sciences has become a wholly-owned subsidiary of Abbott Laboratories. This strategic move highlights Abbott's commitment to enhancing early cancer detection and personalized treatment options.
Read More: Abbott Laboratories Completes Acquisition of Exact Sciences, Strengthens Market Position
Abbott Laboratories Q3 Earnings Report Shows $1.15 Earnings Per Share
Abbott Laboratories reported earnings per share (EPS) of $1.15 for the third quarter, exceeding analysts' expectations. Revenue for the quarter reached $10.2 billion, reflecting a year-over-year increase of 5%. The company has a price-to-earnings (P/E) ratio of 22.4. This performance may influence market sentiment regarding healthcare stocks, particularly in the context of ongoing economic recovery.
Read More: Abbott Laboratories Q3 Earnings Report Shows $1.15 Earnings Per ShareMore Health Care stocks
Frequently asked questions
Is Abbott Laboratories in the S&P 500?
Yes. Abbott Laboratories trades as ABT and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is ABT in?
ABT sits in the Health Care sector of the S&P 500.
Where can I find the latest ABT news?
Right here. This page collects recent ABT news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Abbott Laboratories's stock price?
ABT last traded at about $104.89. Prices move all through the session, so this is the latest quote rather than a live one.
What is Abbott Laboratories's market cap?
ABT is worth roughly $181.50B. Market cap is the share price times the number of shares outstanding.
What is ABT's P/E ratio?
ABT trades at a trailing P/E ratio of about 33.8. The ratio compares the share price with earnings per share over the past year.